Literature DB >> 29793953

N-Linked Glycosylation Is Not Essential for Sodium Taurocholate Cotransporting Polypeptide To Mediate Hepatitis B Virus Infection In Vitro.

Jiwon Lee1, Li Zong1,2, Alexander Krotow1, Yanli Qin3, Lucy Jia1, Jiming Zhang3, Shuping Tong1,2, Jisu Li4.   

Abstract

Sodium taurocholate cotransporting polypeptide (NTCP) has been identified as a hepatitis B virus (HBV) receptor, and its overexpression in HepG2 cell lines leads to efficient secretion of hepatitis B e antigen (HBeAg) following challenge with a large dose of cell culture-derived HBV (cHBV) particles. However, NTCP-reconstituted HepG2 cells are inefficiently infected by patient serum-derived HBV (sHBV) and release very little hepatitis B surface antigen (HBsAg) following cHBV infection, unlike differentiated HepaRG cells, which are naturally susceptible to both cHBV and sHBV particles. Here, we investigated whether NTCP could explain the different behaviors of the two cell types. Endogenous NTCP protein from differentiated HepaRG cells was unglycosylated despite wild-type coding sequence. HepaRG cells stably transfected with an epitope-tagged NTCP expression construct displayed higher sHBV but not cHBV susceptibility than cells transfected with the null mutant. Tagged NTCP introduced to both HepG2 and HepaRG cells was glycosylated, with N5 and N11 being sites of N-linked glycosylation. Mutating N5, N11, or both did not alter cell surface availability of NTCP or its subcellular localization, with both the singly glycosylated and nonglycosylated forms still capable of mediating cHBV infection in HepG2 cells. In conclusion, nonglycosylated NTCP is expressed by differentiated HepaRG cells and capable of mediating cHBV infection in HepG2 cells, but it cannot explain differential susceptibility of HepaRG and HepG2/NTCP cells to cHBV versus sHBV infection and different HBsAg/HBeAg ratios following cHBV infection. The responsible host factor(s) remains to be identified.IMPORTANCE HBV can infect differentiated HepaRG cells and also HepG2 cells overexpressing NTCP, the currently accepted HBV receptor. However, HepG2/NTCP cells remain poorly susceptible to patient serum-derived HBV particles and release very little hepatitis B surface antigen following infection by cell culture-derived HBV. We found differentiated HepaRG cells expressed nonglycosylated NTCP despite a wild-type coding sequence. NTCP introduced to HepG2 cells was glycosylated at two N-linked glycosylation sites, but mutating either or both sites failed to prevent infection by cell culture-derived HBV or to confer susceptibility to serum-derived HBV. Overexpressing NTCP in HepRG cells did not increase infection by cell culture-derived HBV or distort the ratio between the two viral antigens. These findings suggest that host factors unique to HepaRG cells are required for efficient infection by serum-derived HBV, and factors other than NTCP contribute to balanced viral antigen production following infection by cell culture-derived HBV.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HepG2; HepaRG; N-linked glycosylation; hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; infection; sodium taurocholate cotransporting polypeptide

Mesh:

Substances:

Year:  2018        PMID: 29793953      PMCID: PMC6052319          DOI: 10.1128/JVI.00732-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.

Authors:  Frédéric M Vaz; Coen C Paulusma; Hidde Huidekoper; Minke de Ru; Cynthia Lim; Janet Koster; Kam Ho-Mok; Albert H Bootsma; Albert K Groen; Frank G Schaap; Ronald P J Oude Elferink; Hans R Waterham; Ronald J A Wanders
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

2.  Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver.

Authors:  T Gerloff; A Geier; B Stieger; B Hagenbuch; P J Meier; S Matern; C Gartung
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

3.  Short-term regulation of bile acid uptake by microfilament-dependent translocation of rat ntcp to the plasma membrane.

Authors:  J A Dranoff; M McClure; A D Burgstahler; L A Denson; A R Crawford; J M Crawford; S J Karpen; M H Nathanson
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

4.  Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro.

Authors:  Gustaf E Rydell; Kasthuri Prakash; Heléne Norder; Magnus Lindh
Journal:  Virology       Date:  2017-06-10       Impact factor: 3.616

5.  Characterization of contrasting features between hepatitis B virus genotype A and genotype D in small envelope protein expression and surface antigen secretion.

Authors:  Fei Zhang; Xiaoli Tang; Tamako Garcia; Anna S Lok; Yongxiang Wang; Haodi Jia; Yanli Qin; Chaoyang Chen; Yumei Wen; Jisu Li; Shuping Tong
Journal:  Virology       Date:  2017-01-23       Impact factor: 3.616

6.  Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity.

Authors:  Yanli Qin; Xiaoli Tang; Tamako Garcia; Munira Hussain; Jiming Zhang; Anna Lok; Jack Wands; Jisu Li; Shuping Tong
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

7.  Postnatal changes in N-linked oligosaccharides of glycoproteins in rat liver.

Authors:  S Kato; S Oda-Tamai; N Akamatsu
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

8.  Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration.

Authors:  P Gripon; C Diot; C Guguen-Guillouzo
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

Review 9.  The SLC10 carrier family: transport functions and molecular structure.

Authors:  Barbara Döring; Thomas Lütteke; Joachim Geyer; Ernst Petzinger
Journal:  Curr Top Membr       Date:  2012       Impact factor: 3.049

10.  N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.

Authors:  Monique D Appelman; Anindita Chakraborty; Ulrike Protzer; Jane A McKeating; Stan F J van de Graaf
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

View more
  5 in total

1.  In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide.

Authors:  Connie Le; Reshma Sirajee; Rineke Steenbergen; Michael A Joyce; William R Addison; D Lorne Tyrrell
Journal:  Viruses       Date:  2021-01-12       Impact factor: 5.048

Review 2.  Post-translational Modification Control of HBV Biological Processes.

Authors:  Fan Yang
Journal:  Front Microbiol       Date:  2018-11-01       Impact factor: 5.640

3.  E-cadherin Plays a Role in Hepatitis B Virus Entry Through Affecting Glycosylated Sodium-Taurocholate Cotransporting Polypeptide Distribution.

Authors:  Qin Hu; Feifei Zhang; Liang Duan; Bo Wang; Yuanyuan Ye; Pu Li; Dandan Li; Shengjun Yang; Lan Zhou; Weixian Chen
Journal:  Front Cell Infect Microbiol       Date:  2020-02-27       Impact factor: 5.293

4.  An Immortalized Hepatocyte-like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV.

Authors:  Khanit Sa-Ngiamsuntorn; Piyanoot Thongsri; Yongyut Pewkliang; Adisak Wongkajornsilp; Pattida Kongsomboonchoke; Phichaya Suthivanich; Suparerk Borwornpinyo; Suradej Hongeng
Journal:  Viruses       Date:  2019-10-16       Impact factor: 5.048

Review 5.  Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery.

Authors:  Dariusz Zakrzewicz; Joachim Geyer
Journal:  Biomedicines       Date:  2022-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.